Physician profile
Andre S Cohen
NPI 1679597884
$3,703.99
in general payments reported to CMS, 2019-2025
20 companies · $972 in 2025
The $972 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $206 · 2021: $471 · 2022: $351 · 2023: $544 · 2024: $768 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,283.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,015.33 | 2019-2025 | Clareon, Argos, Clareon Panoptix Pro |
| Johnson & Johnson Surgical Vision, INC. | $645.17 | 2019-2025 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Rxsight INC | $528.32 | 2022-2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Dompe US, INC. | $214.90 | 2019-2025 | Oxervate |
| Glaukos Corporation | $184.32 | 2021-2024 | Ce-Marked Kxla System |
| Abbvie INC. | $161.67 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| New World Medical,INC. | $157.97 | 2023-2024 | Streamline, Kahook Dual Blade, Clearpath |
| Bausch & Lomb Americas INC. | $124.95 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Sun Pharmaceutical Industries INC. | $117.14 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $112.51 | 2019-2020 | |
| Akorn Operating Company LLC | $83.98 | 2021 | |
| Oyster Point Pharma, INC. | $83.91 | 2022-2024 | Tyrvaya |
| Allergan, INC. | $70.79 | 2020-2021 | |
| Amgen INC. | $45.09 | 2024 | Tepezza |
| Ocular Therapeutix, INC. | $43.74 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $28.35 | 2019 | |
| Lombart Brothers, INC. | $27.92 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.33 | 2021 | |
| Astellas Pharma US INC | $18.95 | 2023 | Izervay |
| Carl Zeiss Meditec, INC. | $15.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.